Skip to content

Medical emergency? What to do

Many U.S. post-approval drug studies unfinished

3-RXPublished March 7, 20063 min read

Key points

  • Nearly two thirds of more than 1,200 post-approval drug studies promised by the manufacturers have yet to start, according to U.S. government statistics released on Friday.
  • "The percentages of open commitments, pending, ongoing, delayed, terminated and submitted (studies) are all in the same ballpark range," Dr.
  • Some studies were required in exchange for faster approval of drugs for life-threatening diseases such as cancer or AIDS.
  • In its report released Friday, the FDA said 65 percent of 1,231 open studies for chemical-based drugs were "pending," meaning they had not started but were not yet considered delayed.

Nearly two thirds of more than 1,200 post-approval drug studies promised by the manufacturers have yet to start, according to U.S. government statistics released on Friday.

An annual report by the Food and Drug Administration showed little change from recent years in the percentage of studies that remain unfinished, officials said.

"The percentages of open commitments, pending, ongoing, delayed, terminated and submitted (studies) are all in the same ballpark range," Dr. John Jenkins, director of the FDA's Office of New Drugs, told reporters.

Most of the studies were voluntarily agreed to at the time of FDA approval, and the agency has no power to force companies to complete the research.

Some studies were required in exchange for faster approval of drugs for life-threatening diseases such as cancer or AIDS. In those cases, the FDA can withdraw a drug's approval if a study goes unfinished, but has never done so. Officials did not say how many drugs had requirements for mandatory studies.

Last month, the agency said it would seek suggestions from an outside group on ways to make sure drug companies complete more post-approval studies. Regulators say the follow-up data can provide important new details about safety and effectiveness.

In its report released Friday, the FDA said 65 percent of 1,231 open studies for chemical-based drugs were "pending," meaning they had not started but were not yet considered delayed. Many of those studies were agreed to years ago before the FDA gave timelines, which makes it difficult to say if they are behind schedule, Jenkins said.

In the past few years, the FDA has attached schedules for study enrollment and completion.

Two percent of the studies were considered delayed, while 19 percent were on schedule. Drug makers had submitted final reports on 14 percent of the studies.

Jenkins said about 300 of the 797 pending studies were requested in fiscal years 2004 or 2005, "so you might not be surprised those are still pending." He said it can easily take six to 12 months to get a study up and running.

For biologic drugs derived from living things, only 37 percent were pending and 29 percent were on schedule. But 17 percent were deemed delayed.

The drug industry said it was time-consuming and sometimes difficult to enroll patients in studies of drugs already on the market. The FDA report should not be "distorted," said Alan Goldhammer, associate vice president for scientific and regulatory affairs at the Pharmaceutical Research and Manufacturers of America.

"Pending does not mean delayed. It does mean, however, that the immense and vitally important tasks of developing research protocols, finding investigators and researchers and even recruiting patients to participate in the study is in process," he said in a statement.

Consumer group Public Citizen said Congress should give the FDA power to levy large penalties to punish companies that leave studies unfinished.

"The great majority of post-marketing studies address safety issues, at least in part, so patients and physicians are denied critical safety information when these studies are not completed in a timely fashion," Peter Lurie, deputy director of Public Citizen's Health Research Group, said in a statement.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.